Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Eur J Cancer. 2020 Jan 8;126:78–90. doi: 10.1016/j.ejca.2019.12.006

Figure 5. Competing risk analysis to assess association between early progression and transformation in MSKCC patients treated with R-chemotherapy.

Figure 5.

Patients were categorized as early progressors within 1 year, early progressors between 1–2 years, and PFS24 achievers who lack progression within 2 years. The competing events were transformation or death without transformation. The risk of transformation based on time from risk defining event (dashed lines) were compared to the risk of death not attributed to transformation (solid lines).